ClinicalTrials.gg
RecruitingNCT07946367DUETUpdated Nov 18, 2026

Dual-targeting of B & T Cell Pathways Evaluation Trial

A Phase 1/2 interventional study of DFI205 bispecific antibody in Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc), sponsored by Diabetes Free, Inc.. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Diabetes Free, Inc. · Phase 1/2, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 362 studies in Arthritis, Rheumatoid with a site in Germany — 27 open to participants now, 50 under way, 3 of them phase 3. Arthritis, Rheumatoid · Germany.

Planned enrollment
235th of 297
72 · median 259
Started
2026
with 6 others
Phase 1/2
17 of 362
5 open now
Primary completion
2028-08
later than 33 of 49 live
Registered
361st of 362
by date

Among the 362 studies in Arthritis, Rheumatoid with a site in Germany, this one is the 235th largest by planned enrollment of the 297 interventional ones that give a count, is one of 7 that started in 2026, is one of 17 in phase 1/2, reaches primary completion later than 33 of the 49 other live ones, and was the 361st registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

27 of the 362 studies in Arthritis, Rheumatoid with a site in Germany are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 362 studies in Arthritis, Rheumatoid with a site in Germany, or all of them as a file.
02

Study summary

This is a first-in-human study of DFI205, an investigational bispecific antibody that binds CD20 and CD40, with the goal of targeting both B- and T-cell function in adults with active systemic autoimmune rheumatic diseases (SARDs) despite standard therapy. In Phase 1, participants with RA, SLE, SSc or IIM will receive a single dose at increasing dose levels to establish safety and initial treatment response. The selected dose will be carried forward into Phase 2a, where participants will receive monthly doses to assess safety and treatment response.

03

Conditions studied

  • Rheumatoid Arthritis (RA)
  • Systemic Lupus Erythematosus (SLE)
  • Systemic Sclerosis (SSc)
  • Idiopathic Inflammatory Myopathies (IIM)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants, age 18 years and older.
  • Able to understand and comply with all scheduled visits, treatment plans, laboratory tests, and other procedures of the study protocol including ability to provide written .
  • Maintaining a stable, qualifying, standard of care regimen for ≥4 weeks prior to screening as treatment for a qualifying primary diagnosis (RA, SLE, SSc, IIM including the disease-specific criteria listed below):
  • Rheumatoid Arthritis (RA) participants must have, 1) positivity of anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor (RF); 2) moderate to highly active disease despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months; secondary Sjögren's disease diagnosis is acceptable as long as other criteria are met.
  • Systemic Lupus Erythematosus (SLE) participants must have, 1) positivity of anti-nuclear-antibodies (ANA) and/or anti-dsDNA and/or anti-histone and/or anti-nucleosome and/or anti-Sm antibodies; 2) active disease despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months.
  • Systemic Sclerosis (SSc) participants must have, 1) positivity for at least one SSc-associated autoantibody; 2) mRSS score >10 units or interstitial lung disease (ILD) including pulmonary involvement despite treatment with at least 2 lines of standard therapy; 3) disease duration ≤ 5 years (from onset of first non-Raynaud manifestation); 4) not eligible for or declining hematopoietic stem-cell transplantation
  • Idiopathic Inflammatory Myopathies (IIM) participants must have, 1) positivity for at least one myositis-specific antibody; 2) active myositis or presence of ILD defined by clinically relevant pulmonary involvement despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of a non-rheumatic disease requiring therapeutic or immune therapy or modulation (e.g., neuropathy requiring IVIg, Multiple Sclerosis). Milder autoimmune conditions requiring replacement or exocrine functional therapies are acceptable (e.g., Type 1 diabetes, Celiac Disease, Autoimmune Thyroid Disease if on stable treatment for at least 6 months).
  • History of any pre-existing liver disease, including cirrhosis, acute liver disease, or chronic liver disease (unless considered stable for >6 months and required screening laboratory tests meet criteria).
  • Severe unresolved cardiac disease.
  • Estimated (GFR) \<30 mL/min/1.73 m2.
  • Presence or history of active infections, including , , (HIV), Human T-lymphotropic virus (HTLV) or tuberculosis. Participants with laboratory evidence of active infection are excluded even in the absence of clinical evidence of active infection. Participants with mild skin and nail fungal infections are not excluded.
  • Acute infection requiring systemic therapy or hospitalization within 30 days before screening.
  • Invasive aspergillus, histoplasmosis, or coccidioidomycosis infection within one year prior to enrollment.
  • Any history of in the 5 years before screening except for completely resected squamous or basal cell carcinoma of the skin.
  • Primary or secondary immunodeficiency, including hypogammaglobulinemia.
  • History or evidence of progressive multifocal leukoencephalopathy (PML) or other demyelinating disorders.
  • Allergies to humanized monoclonal antibodies or severe post-treatment reactions other than localized injection site reaction, to any biological molecule.
  • Systemic therapy or adrenocorticotropic hormone (ACTH) use within 30 days prior to screening and within entire duration of screening period prior to beginning of study treatment, unless prescribed as background therapy.
  • Intolerance of or to oral or IV corticosteroids.
  • Treatment with other biologic or non-biologic agents (e.g., anti-CD20 therapies, TNF inhibitors, azathioprine, cyclosporine, methotrexate, or mycophenolate) within 6 months prior to screening, unless prescribed as background therapy.
  • The participant has taken another investigational drug within 3 months or 5-half-lives before the screening visit, whichever is longer, or any investigational drug that has depleted a cell type or line without recovery.
  • Previous treatment with anti-CD19 agents, anti-CD38 agents, bispecific anti-CD19/CD3 T cell engaging therapies, adoptive T cell therapy or any prior gene therapy product.
  • Received any form of stem cell transplant.
  • Administration of (s) within 12 weeks prior to and 12 weeks after the completion of DFI205 administration or any planned receipt during the study that cannot be delayed. Vaccinations should be up-to-date as per local clinical practice.
  • Plasmapheresis within 3 months prior to first dose of DFI205
  • Positive pregnancy test, presently breast-feeding, (female participants) or unwillingness to use highly effective measures for the duration of the study and 6 months after discontinuation.
  • Any condition, including the presence of relevant abnormalities in vital parameters or laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Phase 1 Single Ascending Dose Escalation

    Intravenous (IV) infusion of DFI205 at ascending dose levels.

    Drug: DFI205 bispecific antibody

  • Experimental
    Phase 2a Multi-Dose

    DFI205 monthly IV infusions at the recommended Phase 2 dose

    Drug: DFI205 bispecific antibody

Interventions

  • DrugDFI205 bispecific antibody

    A bispecific monoclonal antibody that binds to both CD20 and CD40 receptors on cells.

06

What researchers measure

Primary outcomes

  1. To evaluate the initial safety and tolerability of DFI205 in adults with SARDs

    Numbers and types of all adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Up to 1 year post-dosing

  2. To monitor immune reconstitution after completion of dosing with DFI205

    Time to normalized peripheral blood B cell counts compared to baseline.

    Time frame: Up to 1 year post-dosing

  3. To monitor immune response to DFI205

    Number of participants with anti-drug antibody development.

    Time frame: Up to 1 year post-dosing

Secondary outcomes

  1. To evaluate the ability of DFI205 to induce an objective response in adults with RA

    Overall Response Rate (ORR) measured by proportion of participants achieving either low-disease activity (DAS28-CRP ≤ 3.2, DAS28-ESR ≤3.2, SDAI≤11, CDAI≤10) or remission criteria (DAS28-CRP \< 2.6, DAS28-ESR \<2.6, SDAI ≤3.3, CDAI ≤ 2.8,Boolean 2.0 remission criteria) combined

    Time frame: 24 weeks post-dosing

  2. To evaluate the ability of DFI205 to induce an objective response in adults with SLE

    Overall Response Rate (ORR) measured by fulfillment of DORIS remission criteria

    Time frame: 24 weeks post-dosing

  3. To evaluate the ability of DFI205 to induce an objective response in adults with SSc

    Overall Response Rate (ORR) measured by proportion of participants achieving either modified Rodnan Skin Score (mRSS) decrease of \>5 points and ≥ 25% decrease from baseline or no progression of interstitial lung disease (ILD progression defined as FVC decline \>10%, or 5-10% plus worsening respiratory symptoms or HRCT progression) combined

    Time frame: 24 weeks post-dosing

  4. To evaluate the ability of DFI205 to induce an objective response in adults with IIM

    Overall Response Rate (ORR) measured by achievement of major response (ACR/EULAR 2016 Myositis Response Criteria Total Improvement Score ≥ 60)

    Time frame: 24 weeks post-dosing

Other outcomes

  1. To evaluate the ability of DFI205 to reduce disease activity in adults with RA

    Change in tender joint count (TJC28) compared to baseline

    Time frame: 24 weeks post-dosing

  2. To evaluate the ability of DFI205 to reduce disease activity in adults with RA

    Change in swollen joint count (SJC28) compared to baseline

    Time frame: 24 weeks post-dosing

  3. To evaluate the ability of DFI205 to reduce disease activity in adults with SLE

    Change in British Isles Lupus Assessment Group (BILAG-2004) score compared to baseline

    Time frame: 24 weeks post-dosing

  4. To evaluate the ability of DFI205 to reduce disease activity in adults with SSc

    Change in mRSS (0=no thickening, 3=severe thickening) compared to baseline

    Time frame: 24 weeks post-dosing

  5. To evaluate the ability of DFI205 to reduce disease activity in adults with IIM

    Change in creatine phosphokinase (CPK) compared to baseline

    Time frame: 24 weeks post-dosing

  6. To evaluate the ability of DFI205 to reduce disease activity in adults with IIM

    Change in muscle strength (MMT8 score) compared to baseline

    Time frame: 24 weeks post-dosing

  7. To evaluate change in erythrocyte sedimentation rate (ESR) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.

    Time frame: Up to 1 year post-dosing

  8. To evaluate change in C-reactive protein (CRP) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.

    Time frame: Up to 1 year post-dosing

  9. To evaluate change in interleukin-6 (IL-6) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.

    Time frame: Up to 1 year post-dosing

  10. To evaluate change in tumor necrosis factor-alpha (TNF-α) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.

    Time frame: Up to 1 year post-dosing

  11. To investigate the pharmacokinetics of DFI205

    Blood samples will be collected to quantitate serum concentrations of DFI205

    Time frame: Up to 1 year post-dosing

  12. To investigate the pharmacodynamics of DFI205 in blood

    Proportions of immune cell subsets in blood by FACS analysis over the course of the study.

    Time frame: Up to 1 year post-dosing

  13. To investigate the secondary lymphoid system pharmacodynamics of DFI205

    Proportions of disease-specific lymph node cell populations over the course of the study.

    Time frame: Up to 1 year post-dosing

  14. To investigate soluble CD40 pharmacodynamics of DFI205

    Soluble CD40 receptor/ligand blood concentrations over the course of the study treatments.

    Time frame: Up to 1 year post-dosing

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Aug 2028, 20 months later.

Of 29 phase 1/2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's planned 20 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 18, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Aug 2028
CompletionEst.
Dec 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946367
Lead sponsor
Diabetes Free, Inc.
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Bernhard Remes
Contact
info@diabetesfree.com
0049641944360
Georg Schett, M.D.
principal investigator · University of Erlangen-Nürnberg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion